IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca ... imply any form of partnership ...

AstraZeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) to the FDA for accelerated ... making it the most common form. By the end of the year, it is estimated that there ...

AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the ... on this site does not imply any form of partnership, agency, or endorsement.

However, AstraZeneca and its partner Daiichi Sankyo withdrew their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of ...

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. The green light for ...

and its partner Daiichi Sankyo have decided to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung ...

The FDA has granted Priority Review designation to AstraZeneca’s supplemental Biologics License Application (sBLA ... bladder cancer is the ninth most common form of the disease in the world, with ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

AstraZeneca PLC ... to withdraw their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of lung cancer.